6 research outputs found
MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery
The severity of hepatic steatosis is modulated by genetic variants, such as patatin-like
phospholipase domain containing 3 (PNPLA3) rs738409, transmembrane 6 superfamily member
2 (TM6SF2) rs58542926, and membrane-bound O-acyltransferase domain containing 7 (MBOAT7)
rs641738. Recently, mitochondrial amidoxime reducing component 1 (MTARC1) rs2642438 and
hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) rs72613567 polymorphisms were shown to
have protective effects on liver diseases. Here, we evaluate these variants in patients undergoing
bariatric surgery. A total of 165 patients who underwent laparoscopic sleeve gastrectomy and intraoperative liver biopsies and 314 controls were prospectively recruited. Genotyping was performed
using TaqMan assays. Overall, 70.3% of operated patients presented with hepatic steatosis. NASH
(non-alcoholic steatohepatitis) was detected in 28.5% of patients; none had cirrhosis. The increment of
liver fibrosis stage was associated with decreasing frequency of the MTARC1 minor allele (p = 0.03). In
multivariate analysis MTARC1 was an independent protective factor against fibrosis â„ 1b (OR = 0.52,
p = 0.03) and â„1c (OR = 0.51, p = 0.04). The PNPLA3 risk allele was associated with increased hepatic
steatosis, fibrosis, and NASH (OR = 2.22, p = 0.04). The HSD17B13 polymorphism was protective
against liver injury as reflected by lower AST (p = 0.04) and ALT (p = 0.03) activities. The TM6SF2
polymorphism was associated with increased ALT (p = 0.04). In conclusion, hepatic steatosis is common among patients scheduled for bariatric surgery, but the MTARC1 and HSD17B13 polymorphisms
lower liver injury in these individuals
MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis
The clinical picture of autoimmune hepatitis (AIH) varies markedly between patients, potentially due to genetic modifiers. The aim of this study was to evaluate genetic variants previously associated with fatty liver as potential modulators of the AIH phenotype. The study cohort comprised 313 non-transplanted adults with AIH. In all patients, the MARC1 (rs2642438), HSD17B13 (rs72613567), PNPLA3 (rs738409), TM6SF2 (rs58542926), and MBOAT7 (rs641738) variants were genotyped using TaqMan assays. Mitochondrial damage markers in serum were analyzed in relation to the MARC1 variant. Carriers of the protective MARC1 allele had lower ALT and AST (both Pâ<â0.05). In patients treated for AIH forââ„â6 months, MARC1 correlated with reduced AST, ALP, GGT (all Pââ€â0.01), and lower APRI (Pâ=â0.02). Patients carrying the protective MARC1 genotype had higher total antioxidant activity (Pâ<â0.01) and catalase levels (Pâ=â0.02) in serum. The PNPLA3 risk variant was associated with higher MELD (Pâ=â0.02) in treated patients, whereas MBOAT7 increased the odds for liver cancer (ORâ=â3.71). None of the variants modulated the risk of death or transplantation. In conclusion, the MARC1 polymorphism has protective effects in AIH. Genotyping of MARC1, PNPLA3, and MBOAT7 polymorphisms might help to stratify patients with AIH
Liver phenotypes in PCOS: Analysis of exogenous and inherited risk factors for liver injury in two European cohorts
Background & Aims
Fatty liver disease (FLD) is common in women with polycystic ovary syndrome (PCOS). Here, we use non-invasive tests to quantify liver injury in women with PCOS and analyse whether FLD-associated genetic variants contribute to liver phenotypes in PCOS.
Methods
Prospectively, we recruited women with PCOS and controls at two university centres in Germany and Poland. Alcohol abuse was regarded as an exclusion criterion. Genotyping of variants associated with FLD was performed using TaqMan assays. Liver stiffness measurements (LSM), controlled attenuation parameters (CAP) and non-invasive HSI, FLI, FIB-4 scores were determined to assess hepatic steatosis and fibrosis.
Results
A total of 42 German (age range 18â53âyears) and 143 Polish (age range 18â40âyears) women with PCOS, as well as 245 German and 289 Polish controls were recruited. In contrast to Polish patients, Germans were older, presented with more severe metabolic profiles and had significantly higher LSM (median 5.9âkPa vs. 3.8âkPa). In the German cohort, carriers of the PNPLA3 p.I148M risk variant had an increased LSM (p = .01). In the Polish cohort, the minor MTARC1 allele was linked with significantly lower serum aminotransferases activities, whereas the HSD17B13 polymorphism was associated with lower concentrations of 17-OH progesterone, total testosterone, and androstenedione (all pâ<â.05).
Conclusions
FLD is common in women with PCOS. Its extent is modulated by both genetic and metabolic risk factors. Genotyping of variants associated with FLD might help to stratify the risk of liver disease progression in women suffering from PCOS.Peer Reviewe
Liver phenotypes in PCOS : Analysis of exogenous and inherited risk factors for liver injury in two European cohorts
Background & Aims
Fatty liver disease (FLD) is common in women with polycystic ovary syndrome (PCOS). Here, we use non-invasive tests to quantify liver injury in women with PCOS and analyse whether FLD-associated genetic variants contribute to liver phenotypes in PCOS.
Methods
Prospectively, we recruited women with PCOS and controls at two university centres in Germany and Poland. Alcohol abuse was regarded as an exclusion criterion. Genotyping of variants associated with FLD was performed using TaqMan assays. Liver stiffness measurements (LSM), controlled attenuation parameters (CAP) and non-invasive HSI, FLI, FIB-4 scores were determined to assess hepatic steatosis and fibrosis.
Results
A total of 42 German (age range 18â53âyears) and 143 Polish (age range 18â40âyears) women with PCOS, as well as 245 German and 289 Polish controls were recruited. In contrast to Polish patients, Germans were older, presented with more severe metabolic profiles and had significantly higher LSM (median 5.9âkPa vs. 3.8âkPa). In the German cohort, carriers of the PNPLA3 p.I148M risk variant had an increased LSM (p = .01). In the Polish cohort, the minor MTARC1 allele was linked with significantly lower serum aminotransferases activities, whereas the HSD17B13 polymorphism was associated with lower concentrations of 17-OH progesterone, total testosterone, and androstenedione (all pâ<â.05).
Conclusions
FLD is common in women with PCOS. Its extent is modulated by both genetic and metabolic risk factors. Genotyping of variants associated with FLD might help to stratify the risk of liver disease progression in women suffering from PCOS
Serum level of vitamin D is associated with severity of coronary atherosclerosis in postmenopausal women
SIMPLE SUMMARY: Postmenopausal women experience rapid progression of coronary artery disease. Recent studies have shown that vitamin D deficiency might be considered a modifiable risk factor for cardiovascular diseases. The main object of this study was to analyze the potential cardioprotective effect of 25(OH)D and its influence on coronary atherosclerosis assessed by Coronary Artery Surgery Study Score (CASSS). We prospectively enrolled over 300 postmenopausal women undergoing coronary angiography. Our study showed that women with more severe coronary atherosclerosis have significantly lower serum levels of 25(OH)D. We also presented that vitamin D serves as an independent determinant of the CASS Score. Our study provides further evidence that low vitamin D level appears to be a potential risk factor for coronary artery disease. ABSTRACT: Background: Postmenopausal women experience rapid progression of coronary artery disease. Vitamin D deficiency appears to be a modifiable risk factor for cardiovascular diseases. This study aimed to analyze the impact of 25-hydroxyvitamin D3 (25(OH)D) level on the severity of coronary atherosclerosis and its potential cardioprotective effect in postmenopausal women. Material and Methods: The study prospectively recruited 351 women in postmenopausal age undergoing coronary angiography. The severity of coronary atherosclerosis was assessed using the Coronary Artery Surgery Study Score (CASSS). A level of 25(OH)D was measured with electrochemiluminescence. Results: Women with more severe coronary atherosclerosis have significantly lower 25(OH)D serum level (p = 0.0001). Vitamin D (ÎČ = â0.02; p = 0.016), hypertension (ÎČ = 0.44; p = 0.025), age (ÎČ = 0.02; p = 0.003), and history of MI (ÎČ = 0.63; p < 0.0001), were shown as CASSS determinants. Age, hyperlipidemia, and history of MI were found to determine the level of vitamin D (all p < 0.05). Women with a three-vessel disease hospitalized due to ACS, with a history of MI, hyperlipidemia and hypertension presented the lowest vitamin D level. Conclusions: Our study showed that lower serum 25(OH)D in postmenopausal women is associated with more significant stenosis in the coronary arteries. Therefore, we suggest considering low vitamin D level as a potential risk factor for coronary artery disease
COVIDâ19 and nonâalcoholic fatty liver disease: Two intersecting pandemics
Background: Initial evidence from China suggests that most vulnerable subjects to COVID-19 infection suffer from pre-existing illness, including metabolic abnormalities. The pandemic characteristics and high-lethality rate of COVID-19 infection have raised concerns about interactions between virus pathobiology and components of the metabolic syndrome. Methods: We harmonized the information from the recent existing literature on COVID-19 acute pandemic and mechanisms of damage in non-alcoholic fatty liver disease (NAFLD), as an example of chronic (non-communicable) metabolic pandemic. Results: COVID-19-infected patients are more fragile with underlying metabolic illness, including hypertension, cardiovascular disease, type 2 diabetes, chronic lung diseases (e.g. asthma, chronic obstructive pulmonary disease and emphysema) and metabolic syndrome. During metabolic abnormalities, expansion of metabolically active fat ('overfat condition') parallels chronic inflammatory changes, development of insulin resistance and accumulation of fat in configuring NAFLD. The deleterious interplay of inflammatory pathways chronically active in NAFLD and acutely in COVID-19-infected patients, can explain liver damage in a subgroup of patients and might condition a worse outcome in metabolically compromised NAFLD patients. In a subgroup of patients with NAFLD, the underlying liver fibrosis might represent an additional and independent risk factor for severe COVID-19 illness, irrespective of metabolic comorbidities. Conclusions: NAFLD can play a role in the outcome of COVID-19 illness due to frequent association with comorbidities. Initial evidences suggest that increased liver fibrosis in NAFLD might affect COVID-19 outcome. In addition, long-term monitoring of post-COVID-19 NAFLD patients is advisable, to document further deterioration of liver damage. Further studies are required in this field